4PELKONEN S,AALTO J,FINNE J,et al.Differential activities of bacteriophage depolymerase on bacterial polysaccharide:binding is essential but degradation is inhibitory in phage infection of K1-defective Escherichia coli[J].Bacterial,1992,174(23):7757-7761.
5LEVIN B R,BULL J J.Population and evolutionary dynamics of phage therapy[J].Nat Rev Microbiol,2004,2(2):166-173.
6PAYNE R J,JANSEN V A.Pharmacokinetic principles of bacteriophage therapy[J].Clin Pharmacokinet,2003,42(4):315-325.
7WELD R J,BUTTS C,HEINEMANN J A.Models of phage growth and their applicability to phage therapy[J].Theor Biol,2004,227(1):1-11.
8FISCHER C R,YOICHI M,UNNO H,et al.The coexistence of Escherichia coli serotype O157:H7 and its specific bacteriophage in continuous culture[J].FEMS Microbiol Lett,2004,241(2):171-177.
9MESYANZHINOV V V,ROBBEN J,GRYMONPREZ B,etal.The genome of bacteriophage fKZ of Pseudomonas aeruginosa[J].Mol Biol,2002,317(1):1-19.
10SCHUCH R,NELSON D,FISCHETTI V A.A bacteriolytic agent that detects and kills Bacillus anthracis[J].Nature,2002,418(6900):884-889.
